Across three Phase III trials, Sanofi’s in-development replacement for Lantus was better at battling low blood sugar than the company’s cash cow insulin product, providing hope for the drugmaker’s diabetes business when its blockbuster goes off patent next year.

…read more

Source: Sanofi’s Lantus heir beats its forebear in controlling diabetes


0 No comments